Comparison of equations with estimate renal function to predict serum vancomycin concentration in patients with spinal cord injury - Does the use of cystatin c improve accuracy?

Therapeutic Drug Monitoring

Volumn 36, Issue 5, 2014, Pages 632-639

  De Carolis, Douglas D ^a   Thorson, Joey G ^a   Marraffa, Rebecca A ^a   Clairmont, Megan A ^a   Kuskowski, Michael A ^b,c  

^a Minneapolis Veterans Affairs Health Care System   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

creatinine; cystatin C; pharmacokinetics; spinal cord injury; vancomycin

Indexed keywords

CREATININE; CYSTATIN C; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTATIN C BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; ELIMINATION RATE CONSTANT; FEMALE; HEALTH CARE COST; HUMAN; KIDNEY FUNCTION; MALE; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; SPINAL CORD INJURY; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; AGED; BLOOD; DRUG MONITORING; EVALUATION STUDY; KIDNEY FUNCTION TEST; METABOLISM; PROCEDURES; SENSITIVITY AND SPECIFICITY; STANDARDS;

AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CYSTATIN C; DRUG MONITORING; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPINAL CORD INJURIES; VANCOMYCIN;

EID: 84930169502     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000065     Document Type: Article

References (43)

1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
2. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
3. Levey AS, Stevens LA, Schmid CH, et al; for the Chronic Kidney Disease Epidemiology Collaboration. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
4. Perrone RD, Madias NE, Levey AS. S. Cr. As an index of renal function: new insights into old concepts. Clin Chem. 1992;38:1933-1953.
5. National Kidney Disease Education Program. Chronic kidney disease and drug dosing: information for providers (Revised January 2010). Available at: http://www. nkdep. nih. gov/resources/ckd-drug-dosing-508. pdf. Accessed August 30, 2013.
6. Mirahmadi MK, Byrne C, Barton C, et al. Prediction of creatinine clearance from serum creatinine in spinal cord injury patients. Paraplegia. 1983;21:23-29.
7. Lee JP, Wang YJ. Testing the predictive ability of the "spinal cord injury equation" in estimating vancomycin clearance. Am J Health Syst Pharm. 2013;70:669-674.
8. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest. 1985;45:97-101.
9. Jacobsson B, Lignelid H, Bergerheim US. Transthyretin and CysC are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology. 1995;26: 559-564.
10. Vinge E, Lindergard B, Nilsson-Ehle P, et al. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest. 1999;59: 587-592.
11. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008;3:348-354.
12. Dharnidharka VR, Kwon C, Stevens G. Cystatin C is superior to S. Cr. As a marker of kidney function: A meta-analysis. Am J Kidney Dis. 2002;40: 221-226.
13. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367: 20-29.
14. Cheung RPF, DiPiro JT. Vancomycin: An update. Pharmacotherapy. 1986;6:153-169.
15. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25:433-437.
16. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
17. Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Applications. 2nd ed. Philadephia, PA: Lea & Febiger; 1989: 238-254.
18. Stevens LA, Nolin T, Levey AS. In reply to 'estimated GFR for drug dosing: A bedside formula,' 'drug dose adjustments in patients with renal impairment,' 'use of the MDRD study equation for drug dosing,' and 'estimated GFR vs creatinine clearance for drug dosing'. Am J Kidney Dis. 2009;54:985-986.
19. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4:183-195.
20. Grubb A, Blirup-Jensen S, Lindstrom V, et al. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med. 2010;48:1619-1621.
21. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39:S76-S110.
22. Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: A systematic review. Ann Intern Med. 2012;156:785-795.
23. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
24. Thomassen SA, Johannesen IL, Erlandsen EJ, et al. Serum cystatin C as a marker of the renal function in patients with spinal cord injury. Spinal Cord. 2002;40:524-528.
25. Jenkins MA, Brown DJ, Ierino FL, et al. Cystatin C for estimation of glomerular filtration rate in patients with spinal cord injury. Ann Clin Biochem. 2003;40:364-368.
26. Beringer PM, Hidayat L, Heed A, et al. GFR estimates using cystatin C are superior to serum creatinine in cystic fibrosis. J Cyst Fibros. 2009;8: 19-25.
27. Delanaye P, Cavalier E, Radermecker RP, et al. Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa. Nephron Clin Pract. 2008;110:c158-c163.
28. Tanaka A, Suemaru K, Otsuka T, et al. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit. 2007;29: 261-264.
29. Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother. 2010;54: 778-782.
30. Suzukia A, Imanishi Y, Nakanob S, et al. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol. 2010;62:901-907.
31. Okamoto G, Sakamoto T, Kimura M, et al. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem. 2007;40:485-490.
32. Mohler JL, Barton SD, Blouin RA, et al. The evaluation of creatinine clearance in spinal cord injury patients. J Urol. 1986; 136:366-369.
33. Sawyer WT, Hutchins K. Assessment and predictability of renal function in spinal cord injury patients. Urology. 1982;19:377-380.
34. Mohler JL, Ellison MF, Flanigan RC. Creatinine clearance prediction in spinal cord injury patients: comparison of 6 prediction equations. J Urol. 1988;139:706-709.
35. Kaji D, Strauss I, Kahn T. Serum creatinine in patients with spinal cord injury. Mt Sinai J Med. 1990;57:160-164.
36. MacDiarmid SA, McIntyre WJ, Anthony A, et al. Monitoring of renal function in patients with spinal cord injury. BJU Int. 2000;85: 1014-1018.
37. Vaidyanathan S, Watt JWH, Singh G, et al. Dosage of once-daily gentamicin in spinal cord injury patients. Spinal Cord. 2000;38: 197-198.
38. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Inter Suppl. 2012;2:1-138.
39. Accetta NA, Gladstone EH, DiSogra C, et al. Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis. 2008; 52:778-787.
40. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis. 1998;32: 23-31.
41. Sepahpanah F, Burns SP, McKnight B, et al. Role of creatinine clearance as a screening test in persons with spinal cord injury. Arch Phys Med Rehabil. 2006;87:524-528.
42. Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75: 652-660.
43. Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule. Available at: http://www. cms. gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab. html. Accessed August 30, 2013.